Pfizer Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Pfizer Bundle
What is included in the product
Detailed Word Document
This outlines Pfizer's products across the BCG Matrix, pinpointing investment, holding, and divestment strategies.
Customizable Excel Spreadsheet
Printable summary optimized for A4 and mobile PDFs, eliminating confusion and saving time.
What You See Is What You Get
Pfizer BCG Matrix
This preview shows the complete Pfizer BCG Matrix you'll download post-purchase. It's the unedited, fully functional version, created for easy strategic implementation within your organization.
BCG Matrix Template
Actionable Strategy Starts Here
Pfizer's BCG Matrix reveals key insights into its diverse product portfolio, from blockbuster drugs to emerging ventures. This framework categorizes products based on market share and growth, offering a snapshot of strategic priorities. It highlights potential "Stars" that drive growth and "Cash Cows" that generate revenue. Identifying "Dogs" and "Question Marks" allows for resource optimization. This is just a glimpse; the full BCG Matrix provides detailed analysis and strategic guidance.
Stars
Vyndaqel/Vyndamax
Vyndaqel/Vyndamax, vital for ATTR-CM, shows robust growth due to better diagnosis and U.S. affordability. These drugs are a major revenue source, with $3.9B in sales for the first nine months of 2024. Expansion in global markets offers further opportunities. Competition may affect growth, so investment is key.
Eliquis
Eliquis, a key star in Pfizer's portfolio, shows strong growth fueled by wider adoption. This anticoagulant has a solid market presence, ensuring steady demand. In 2024, Eliquis achieved a 13% operational growth worldwide, boosted by its popularity. Future success relies on effective marketing and warding off generic competitors.
Oncology Portfolio (Seagen Integration)
Pfizer's oncology portfolio, enhanced by the Seagen acquisition, is a star in its BCG matrix. This strategic move has added key cancer treatments, enhancing its market position. In 2024, the Seagen portfolio generated $3.4 billion in revenue. Future growth hinges on successful clinical trials and regulatory approvals.
Abrysvo
Abrysvo, Pfizer's RSV vaccine, shows strong potential within the BCG Matrix. The recent ACIP vote broadened recommendations to adults aged 50-59 at risk, enhancing its market reach. The European Commission approved Abrysvo in April 2025. This addresses a significant unmet need, with potential for substantial revenue generation.
- 2024 sales of Abrysvo were not available at the time of the last update.
- The ACIP vote in 2024 expanded recommendations.
- European Commission approval happened in April 2025.
- Expanding the target population and reimbursement are key.
Nurtec ODT/Vydura
Nurtec ODT/Vydura, Pfizer's migraine treatments, are shining examples of "Stars" in their BCG Matrix. These drugs have seen impressive demand, especially in the U.S., and are now expanding globally. This growth trajectory firmly places them as rising stars within Pfizer's portfolio, promising significant revenue potential. In 2023, Nurtec ODT/Vydura achieved a 39% operational growth worldwide.
- Demand: Strong in the U.S. and expanding internationally.
- Growth: 39% operational growth globally in 2023.
- Market: Significant revenue potential.
- Strategy: Requires continued innovation and marketing.
Top Performers: Sales and Growth Revealed!
These are high-growth, high-market-share products.
Vyndaqel/Vyndamax, with $3.9B sales in 2024, leads.
Eliquis achieved 13% operational growth worldwide.
Seagen portfolio, $3.4B in 2024, boosts oncology.
| Product | 2024 Sales/Growth | Key Feature |
|---|---|---|
| Vyndaqel/Vyndamax | $3.9B (Sales) | ATTR-CM treatment |
| Eliquis | 13% (Growth) | Anticoagulant |
| Seagen Portfolio | $3.4B (Revenue) | Oncology treatments |
Cash Cows
Prevnar 20
Prevnar 20, a pneumococcal conjugate vaccine, is a Cash Cow for Pfizer. It benefits from a stable market with consistent demand, generating steady revenue with low promotional costs. In 2024, Prevnar 20 sales are projected to reach $6.3 billion. Pfizer's focus is on maintaining market share and optimizing production.
Comirnaty (COVID-19 Vaccine)
Comirnaty, Pfizer's COVID-19 vaccine, remains a substantial revenue source, even after the initial pandemic surge. In 2024, the vaccine is still generating considerable income due to booster shots and ongoing demand. Pfizer expects COVID-19 product revenues to be similar in 2025 to those in 2024. Efficient management of production and distribution is key for sustained profitability.
Enbrel
Enbrel, a key immunology product, remains a strong cash cow for Pfizer. It generates consistent revenue due to its established market presence and efficacy. Despite biosimilar competition, Enbrel contributes significantly to Pfizer's revenue. In 2024, Enbrel's sales were approximately $1.5 billion, showcasing its continued importance.
Xeljanz
Xeljanz, a part of Pfizer's portfolio, is considered a cash cow due to its established market position in treating rheumatoid arthritis and other conditions. This drug has a stable revenue stream, supported by a dedicated patient base. Despite facing competitive pressures, Xeljanz continues to be a significant revenue generator for Pfizer, showcasing its consistent financial performance.
- In 2023, Xeljanz generated approximately $2.5 billion in revenue for Pfizer.
- Xeljanz holds a strong market share in its therapeutic area, competing with other treatments.
- Pfizer's strategic focus includes optimizing pricing and patient support to maintain Xeljanz's market position.
Xtandi
Xtandi, a prostate cancer treatment, is a prime cash cow for Pfizer. It holds a strong market position and consistently generates substantial revenue. In 2024, Xtandi continues to be a significant revenue driver within Pfizer's oncology division. Strategies to expand its use and maintain its competitive edge are crucial for its sustained profitability.
- Xtandi is a cash cow due to its established efficacy.
- It generates substantial revenue for Pfizer.
- Focus is on expanding use and maintaining its competitive edge.
- Xtandi's sales continue to be significant.
Blockbuster Drugs: Billions in Revenue for 2024!
Pfizer's cash cows include Prevnar 20, Comirnaty, Enbrel, Xeljanz, and Xtandi, each generating consistent revenue. These products benefit from established market positions. In 2024, these products are projected to earn billions.
| Product | 2024 Projected Revenue | Notes |
|---|---|---|
| Prevnar 20 | $6.3B | Pneumococcal vaccine. |
| Comirnaty | Significant | COVID-19 vaccine, ongoing demand. |
| Enbrel | $1.5B | Immunology product. |
| Xeljanz | ~$2.5B (2023) | Rheumatoid arthritis treatment. |
| Xtandi | Significant | Prostate cancer treatment. |
Dogs
Older, Off-Patent Products
Older, off-patent products within Pfizer's portfolio, such as Lipitor and Prevnar 13, are categorized as Dogs. These products experience declining sales due to generic competition and loss of exclusivity. They offer limited growth potential and may require costly turnaround plans. In 2024, Pfizer's revenue from off-patent drugs continues to decrease. Divesting or discontinuing these underperforming products is often the most strategic move.
Certain Hospital Products
Certain hospital products within Pfizer's portfolio may exhibit low growth and market share, potentially becoming Dogs in the BCG matrix. These products could be consuming resources without generating substantial returns. In 2023, Pfizer considered selling its hospital drugs unit due to pressure from investors. Divesting underperforming assets is crucial for enhancing overall portfolio performance. Pfizer's 2023 revenue was approximately $58.5 billion, reflecting strategic shifts.
Discontinued Pipeline Assets
Discontinued pipeline assets, such as B7H4V and Zavzpret, are deprioritized by Pfizer. Continued investment in these assets is unlikely to yield significant returns. Pfizer reported $2.9 billion in intangible asset impairments in Q4 2024, mainly due to these assets. Reallocating resources to better opportunities is a smart move.
Products Impacted by IRA
Some of Pfizer's drugs might become 'dogs' due to the Inflation Reduction Act (IRA). This could negatively affect their revenue. The IRA's changes to Medicare Part D impact drug pricing and revenue streams. Pfizer needs to monitor and adjust strategies to reduce potential losses.
- The IRA's negotiation of drug prices could reduce revenue for certain drugs.
- Part D redesign impacts the coverage gap and out-of-pocket costs.
- Pfizer's strategic adjustments are vital for maintaining profitability.
- Focus on drugs with less IRA-related price exposure is crucial.
Biosimilar Competition Casualties
Products like Pfizer's Enbrel and Remicade, facing biosimilar competition, fit the "dogs" category in the BCG matrix. These face substantial revenue declines and low market share due to biosimilar erosion. For example, Remicade's sales dropped significantly in 2024. Managing biosimilar impact is crucial for resource allocation.
- Enbrel and Remicade face biosimilar competition.
- Sales decline and low market share characterize these products.
- Biosimilars erode the revenue of original branded products.
- Proper management of biosimilar impact is vital.
Drug Sales Under Pressure: Declines and Competition
Dogs in Pfizer's portfolio include off-patent drugs and those facing biosimilar competition, experiencing revenue declines. Declining sales and low market share are typical. Remicade's sales declined significantly in 2024 due to biosimilars.
| Category | Characteristics | Examples |
|---|---|---|
| Off-Patent Drugs | Declining sales, generic competition | Lipitor, Prevnar 13 |
| Hospital Products | Low growth, potential divestiture | Hospital unit assets |
| Biosimilar Impacted | Revenue decline, low market share | Enbrel, Remicade |
Question Marks
Sasanlimab
Sasanlimab, Pfizer's anti-PD-1 monoclonal antibody, is in Phase 3 trials for bladder cancer. Its market share is currently minimal, reflecting its investigational status. Success hinges on trial outcomes and regulatory approvals, with potential for significant returns. In 2024, Pfizer invested heavily in its development, with clinical trial costs reaching $1.2 billion.
PF-07220060 (CDK4 Inhibitor)
PF-07220060, a CDK4 inhibitor, is in Pfizer's pipeline for oncology. Its future success is uncertain, dependent on clinical trials and market competition. Pfizer's investment signals its potential as a future blockbuster, with strategic partnerships as vital. In 2024, Pfizer's oncology revenue was $12.3 billion, with new assets aiming to grow this.
Danuglipron (Oral GLP-1RA)
Danuglipron, Pfizer's oral GLP-1RA, targets the booming metabolic disease market. It competes with established injectable options, but offers the convenience of a pill. Pfizer is investing to catch up with Eli Lilly's oral GLP-1RA efforts. In 2024, the global GLP-1 market was estimated at $30B, growing significantly.
Elrexfio (Elranatamab)
Elrexfio (elranatamab) is a question mark in Pfizer's BCG matrix, indicating high growth potential but a low market share. The drug, in Phase III trials for multiple myeloma, faces a competitive landscape. Success hinges on positive trial results and effective market penetration. Pfizer is investing in its oncology pipeline, with Elrexfio as a key asset. Strategic partnerships will be crucial for its future.
- Phase III trials are ongoing, with data expected in 2024-2025.
- Multiple myeloma market is valued at billions, growing annually.
- Pfizer's oncology revenue in 2023 was over $12 billion.
- Elrexfio's success could significantly boost Pfizer's market share.
Next-Generation Paxlovid Formulation
The next-generation Paxlovid formulation is a strategic move by Pfizer, fitting within the BCG Matrix as a "Question Mark." This formulation aims to eliminate drug-drug interaction issues, potentially boosting Paxlovid's prescription rate. Currently, it has low market share but high growth potential if successful. Pfizer's investment in its development is crucial for capturing market share and increasing profits.
- Drug-drug interactions previously limited Paxlovid's use.
- A new formulation could significantly increase prescriptions.
- Success hinges on proving efficacy and safety.
- Pfizer aims to maximize profits through this innovation.
Elrexfio's Phase III Journey: Oncology Growth Ahead?
Elrexfio, a "Question Mark," faces high growth potential in multiple myeloma. It is in Phase III trials and has a low market share. Pfizer’s oncology revenue was over $12 billion in 2023, with Elrexfio aiming to increase this. Success relies on trial results and market penetration.
| Drug | Status | Market Share |
|---|---|---|
| Elrexfio | Phase III | Low |
| Next-gen Paxlovid | Development | Low |
| Danuglipron | Clinical Trials | Low |
BCG Matrix Data Sources
The Pfizer BCG Matrix relies on company reports, market analysis, and industry data for a data-backed assessment.
